bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S1 from Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin
Authors: Yang Bing , Damodaran Shivashankar , Khemees Tariq A. , Filon Mikolaj J. , Schultz Adam , Gawdzik Joseph , Etheridge Tyler , Malin Dmitry , Richards Kyle A. , Cryns Vincent L. , Jarrard David F.
Published: April 2023

All supplementary table
Supplementary Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Authors: Nassar Amin H. , Hamieh Lana , Gray Kathryn P. , Thorner Aaron R. , Fay Andre P. , Lasseter Kathryn D. , Abou Alaiwi Sarah , Nuzzo Pier Vitale , Flippot Ronan , Krajewski Katherine M. , Signoretti Sabina , Choueiri Toni K. , Kwiatkowski David J.
Published: April 2023

Table S1. Clinical and molecular data sets, and statistical analyses for 109 RCC subjects treated with rapalogs.
Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Authors: Varghese Sruthy , Pramanik Snigdha , Williams Leila J. , Hodges Hannah R. , Hudgens Courtney W. , Fischer Grant M. , Luo Catherine K. , Knighton Barbara , Tan Lin , Lorenzi Philip L. , Mackinnon Andrew L. , McQuade Jennifer L. , Hailemichael Yared , Roszik Jason , Peng Weiyi , Vashisht Gopal Y.N.
Published: April 2023

Supplementary figures
Supplementary Tables from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
Authors: Akbulut Ozge , Lengerli Deniz , Saatci Ozge , Duman Elif , Seker Urartu O.S. , Isik Aynur , Akyol Aytekin , Caliskan Burcu , Banoglu Erden , Sahin Ozgur
Published: April 2023

Antibody list and primer sequences
Supplementary Data from Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3
Authors: Rau Alexander , Lieb Wolfgang S. , Seifert Oliver , Honer Jonas , Birnstock Dennis , Richter Fabian , Aschmoneit Nadine , Olayioye Monilola A. , Kontermann Roland E.
Published: April 2023

Supplementary Figures and Table
Figure S2 from A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
Authors: Akbulut Ozge , Lengerli Deniz , Saatci Ozge , Duman Elif , Seker Urartu O.S. , Isik Aynur , Akyol Aytekin , Caliskan Burcu , Banoglu Erden , Sahin Ozgur
Published: April 2023

TACC3 is an independent prognostic factor for breast cancer.
Supplementary Data from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer
Authors: Wen Yunfei , Wang Ying , Chelariu-Raicu Anca , Stur Elaine , Liu Yuan , Corvigno Sara , Bartsch Faith , Redfern Lauren , Zand Behrouz , Kang Yu , Liu Jinsong , Baggerly Keith , Sood Anil K.
Published: April 2023

Full report from Ingenuity Pathway Analysis of the RPPA results.
Figure S6 from Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
Authors: García-Martínez Juan Manuel , Wang Shirley , Weishaeupl Cordula , Wernitznig Andreas , Chetta Paolo , Pinto Catarina , Ho Jason , Dutcher Darrin , Gorman Philip N. , Kroe-Barrett Rachel , Rinnenthal Joerg , Giragossian Craig , Impagnatiello Maria Antonietta , Tirapu Iñigo , Hilberg Frank , Kraut Norbert , Pearson Mark , Kuenkele Klaus Peter
Published: April 2023

Plasma concentrations of BI 905711 in non-tumor bearing BomTac:NMRI-Foxn1nu mice
Figure S2 from Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
Authors: García-Martínez Juan Manuel , Wang Shirley , Weishaeupl Cordula , Wernitznig Andreas , Chetta Paolo , Pinto Catarina , Ho Jason , Dutcher Darrin , Gorman Philip N. , Kroe-Barrett Rachel , Rinnenthal Joerg , Giragossian Craig , Impagnatiello Maria Antonietta , Tirapu Iñigo , Hilberg Frank , Kraut Norbert , Pearson Mark , Kuenkele Klaus Peter
Published: April 2023

Effect of BI 905711-mediated tumor cell death on dendritic cells.
Supplementary Information from PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 nm Diameter Polyethylene Glycols Labeled with Zirconium-89
Authors: Beckford Vera Denis R. , Fontaine Shaun D. , VanBrocklin Henry F. , Hearn Brian R. , Reid Ralph , Ashley Gary W. , Santi Daniel V.
Published: April 2023

Synthetic procedures and supplementary data
Table S3 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Survival of BCBM in BC subtype
Table S1 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Physio-chemical and spectroscopic data of GA11 and MF7
Supplementary Figure 6 from Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Authors: Yamashita Daisuke , Minata Mutsuko , Ibrahim Ahmed N. , Yamaguchi Shinobu , Coviello Vito , Bernstock Joshua D. , Harada Shuko , Cerione Richard A. , Tannous Bakhos A. , La Motta Concettina , Nakano Ichiro
Published: April 2023

Adhesion assay and migration assay using shALDH1A3 in MDA-468 cells
Supplementary table 2 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types
Authors: Topham James T. , Titmuss Emma , Pleasance Erin D. , Williamson Laura M. , Karasinska Joanna M. , Culibrk Luka , Lee Michael K.C. , Mendis Shehara , Denroche Robert E. , Jang Gun-Ho , Kalloger Steve E. , Wong Hui-Li , Moore Richard A. , Mungall Andrew J. , O'Kane Grainne M. , Knox Jennifer J. , Gallinger Steven , Loree Jonathan M. , Mager Dixie L. , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Schaeffer David F. , Renouf Daniel J.
Published: April 2023

Supplemental Table S2 lists all genes differentially expressed in VMP samples.
Supplementary Table 4 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types
Authors: Topham James T. , Titmuss Emma , Pleasance Erin D. , Williamson Laura M. , Karasinska Joanna M. , Culibrk Luka , Lee Michael K.C. , Mendis Shehara , Denroche Robert E. , Jang Gun-Ho , Kalloger Steve E. , Wong Hui-Li , Moore Richard A. , Mungall Andrew J. , O'Kane Grainne M. , Knox Jennifer J. , Gallinger Steven , Loree Jonathan M. , Mager Dixie L. , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Schaeffer David F. , Renouf Daniel J.
Published: April 2023

Supplemental Table S4 lists gene sets significantly enriched among genes down-regulated in VMP samples.
Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Authors: Tewari Krishnansu S. , Sill Michael W. , Monk Bradley J. , Penson Richard T. , Moore David H. , Lankes Heather A. , Ramondetta Lois M. , Landrum Lisa M. , Randall Leslie M. , Oaknin Ana , Leitao Mario M. , Eisenhauer Eric L. , DiSilvestro Paul , Van Le Linda , Pearl Michael L. , Burke James J. , Salani Ritu , Richardson Debra L. , Michael Helen E. , Kindelberger David W. , Birrer Michael J.
Published: April 2023

Supplementary Figure 2
Supplementary Data from Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration
Authors: Ramos Madeleine K. , Mandikian Danielle , Sermeño Lauren N. , King Anna , Dent Alecia T. , Ho Jason , Ulufatu Sheila , Lombana T. Noelle , Spiess Christoph , Go Mary Ann T. , Yu Shang-Fan , Kamath Amrita V. , Ferl Gregory Z. , Boswell C. Andrew
Published: April 2023

Supplementary Data and Methods
Table S1 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Authors: Arai Hiroyuki , Baca Yasmine , Battaglin Francesca , Kawanishi Natsuko , Wang Jingyuan , Soni Shivani , Zhang Wu , Millstein Joshua , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Xiu Joanne , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

Comparison of mutation frequency between ex-GCC and pure GCC
Supplementary appendix from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Authors: Arai Hiroyuki , Baca Yasmine , Battaglin Francesca , Kawanishi Natsuko , Wang Jingyuan , Soni Shivani , Zhang Wu , Millstein Joshua , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Xiu Joanne , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

The methods in assessing microsatellite instability (MSI) and mismatch repair (MMR) status
Figure S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Authors: Arai Hiroyuki , Baca Yasmine , Battaglin Francesca , Kawanishi Natsuko , Wang Jingyuan , Soni Shivani , Zhang Wu , Millstein Joshua , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Xiu Joanne , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

Detected gene mutations and pathway-specific mutations in GCC
Supplementary Table S1 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
Authors: García-Valverde Alfonso , Rosell Jordi , Serna Garazi , Valverde Claudia , Carles Joan , Nuciforo Paolo , Fletcher Jonathan A. , Arribas Joaquín , Politz Oliver , Serrano César
Published: April 2023

Number of mice per treatment arm at baseline used for in vivo experiments.
Supplementary Figure S3 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
Authors: García-Valverde Alfonso , Rosell Jordi , Serna Garazi , Valverde Claudia , Carles Joan , Nuciforo Paolo , Fletcher Jonathan A. , Arribas Joaquín , Politz Oliver , Serrano César
Published: April 2023

Immunohistochemical analysis of the phosphorylation of AKT-serine 473 in A, GIST-T1 and B, GIST-T1/670. Immunohistochemical analysis of the phosphorylation of 4EBP1 in C, GIST-T1 and D, GIST-T1/670. Immunohistochemical analysis of KIT in E, GIST-T1 and F, GIST-T1/670. Graphs are expressed as fold change normalized to vehicle. Differences between treatments was considered to be significant with a p-value * <0.05, ** <0.005, *** <0.001, **** <0.0001.
Supplementary Figure S1 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
Authors: García-Valverde Alfonso , Rosell Jordi , Serna Garazi , Valverde Claudia , Carles Joan , Nuciforo Paolo , Fletcher Jonathan A. , Arribas Joaquín , Politz Oliver , Serrano César
Published: April 2023

Tumor volume (mm3) in four treatment arms at different time points in GIST-T1 (A) and GIST-T1/670 (B) in vivo models. Mean {plus minus} SEM.
Supplementary Materials and Methods from The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade
Authors: Rosette Caridad , Agan Frances J. , Rosette Niccolette , Mazzetti Alessandro , Moro Luigi , Gerloni Mara
Published: April 2023

Materials and Methods
Pharmacokinetics of CB-03-10 from The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade
Authors: Rosette Caridad , Agan Frances J. , Rosette Niccolette , Mazzetti Alessandro , Moro Luigi , Gerloni Mara
Published: April 2023

Pharmacokinetics of CB-03-10
Supplementary Data from Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance
Authors: Hofmann Marco H. , Mani Rajeswaran , Engelhardt Harald , Impagnatiello Maria A. , Carotta Sebastian , Kerenyi Marc , Lorenzo-Herrero Seila , Böttcher Jark , Scharn Dirk , Arnhof Heribert , Zoephel Andreas , Schnitzer Renate , Gerstberger Thomas , Sanderson Michael P. , Rajgolikar Girish , Goswami Swagata , Vasu Sumithira , Ettmayer Peter , Gonzalez Segundo , Pearson Mark , McConnell Darryl B. , Kraut Norbert , Muthusamy Natarajan , Moll Jürgen
Published: April 2023

Supplementary Data including Table S1-Table S5 and Figure S1 - Figure S9
Supplementary Tables 1-2 and Supplementary Figures 1-6 from Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Authors: Zenke Frank T. , Zimmermann Astrid , Sirrenberg Christian , Dahmen Heike , Kirkin Vladimir , Pehl Ulrich , Grombacher Thomas , Wilm Claudia , Fuchss Thomas , Amendt Christiane , Vassilev Lyubomir T. , Blaukat Andree
Published: April 2023

Supplementary Table S1: Evaluation of M3814 (MSC2490484) in kinase assays Supplementary Table S2: In vitro activity of M3814 in combination with a single dose of gamma radiation in a panel of 93 cell lines. Supplementary Table S3: Pharmacokinetic data for M3814 Supplementary Figure S1: 3 Gy IR - M3814 combination profiling: Bliss data Supplementary Figure S2: 70 Drug - M3814 combination profiling: Bliss data Supplementary Figure S3: Concentration of M3814 in vitro, following administration of M3814 intravenously (0.2 mg/kg) or orally (0.5 mg/kg) Supplementary Figure S4: Additional 1-week IR combination efficacy data (A549, BxPC3, Capan-1, HCT-116) Supplementary Figure S5: Scheduling of M3814 relative to IR Supplementary Figure S6: Body weight curves from efficacy studies
Supplemental Figure 3 from Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch
Authors: Goka Erik T. , Chaturvedi Pallavi , Lopez Dayrelis T. Mesa , Lippman Marc E.
Published: April 2023

Supplemental Figure 3. In vitro and In Vivo characterization of GYS32661. (A) Cellular proliferation assay of 786-O cells treated with vehicle, 2.5, and 5 ÃŽÂ¼M GYS32661. (B) Plasma and tumor concentrations of GYS32661 at 0.25, 1, 4, and 8 hour time points.
Table S3 from An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities
Authors: Nicolazzi Céline , Caron Anne , Tellier Alexia , Trombe Marc , Pinkas Jan , Payne Gillian , Carrez Chantal , Guérif Stéphane , Maguin Marie , Baffa Raffaele , Fassan Matteo , Adam Julien , Mangatal-Wade Lydie , Blanc Véronique
Published: April 2023

In vitro cytotoxicity values of SAR566658 and control IgG-DM4 on various tumor cell lines
Supplementary Figure from Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Authors: Lewis Nuruddeen D. , Sia Chang Ling , Kirwin Katherine , Haupt Sonya , Mahimkar Gauri , Zi Tong , Xu Ke , Dooley Kevin , Jang Su Chul , Choi Bryan , Boutin Adam , Grube Andrew , McCoy Christine , Sanchez-Salazar Jorge , Doherty Michael , Gaidukov Leonid , Estes Scott , Economides Kyriakos D. , Williams Douglas E. , Sathyanarayanan Sriram
Published: April 2023

Figures S1 through S6
Supplementary Data Table 2 from Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Authors: Lewis Nuruddeen D. , Sia Chang Ling , Kirwin Katherine , Haupt Sonya , Mahimkar Gauri , Zi Tong , Xu Ke , Dooley Kevin , Jang Su Chul , Choi Bryan , Boutin Adam , Grube Andrew , McCoy Christine , Sanchez-Salazar Jorge , Doherty Michael , Gaidukov Leonid , Estes Scott , Economides Kyriakos D. , Williams Douglas E. , Sathyanarayanan Sriram
Published: April 2023

Fold-change Cytokine Values in Cynomolgus Plasma After Subcutaneous Dosing
Mat & Met S4 from An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities
Authors: Nicolazzi Céline , Caron Anne , Tellier Alexia , Trombe Marc , Pinkas Jan , Payne Gillian , Carrez Chantal , Guérif Stéphane , Maguin Marie , Baffa Raffaele , Fassan Matteo , Adam Julien , Mangatal-Wade Lydie , Blanc Véronique
Published: April 2023

CA6 antigen characterization from tumor cell lines
20201229pdtedSupplementaryFigures.pdf from Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Authors: Lewis Nuruddeen D. , Sia Chang Ling , Kirwin Katherine , Haupt Sonya , Mahimkar Gauri , Zi Tong , Xu Ke , Dooley Kevin , Jang Su Chul , Choi Bryan , Boutin Adam , Grube Andrew , McCoy Christine , Sanchez-Salazar Jorge , Doherty Michael , Gaidukov Leonid , Estes Scott , Economides Kyriakos D. , Williams Douglas E. , Sathyanarayanan Sriram
Published: April 2023

20201229pdtedSupplementaryFigures.pdf from Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Mat & Met S2 from An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities
Authors: Nicolazzi Céline , Caron Anne , Tellier Alexia , Trombe Marc , Pinkas Jan , Payne Gillian , Carrez Chantal , Guérif Stéphane , Maguin Marie , Baffa Raffaele , Fassan Matteo , Adam Julien , Mangatal-Wade Lydie , Blanc Véronique
Published: April 2023

HuDS6 and SAR566658 binding determination
Supplemental Figures from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Authors: Morrison-Smith Chevaun D. , Knox Tatiana M. , Filic Ivona , Soroko Kara M. , Eschle Benjamin K. , Wilkens Margaret K. , Gokhale Prafulla C. , Giles Francis , Griffin Andrew , Brown Bill , Shapiro Geoffrey I. , Zucconi Beth E. , Cole Philip A. , Lemieux Madeleine E. , French Christopher A.
Published: April 2023

supplemental figures
Supplementary Fig S2 from CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Authors: Zeng Ling , Nikolaev Anatoly , Xing Chuan , Della Manna Deborah L. , Yang Eddy S.
Published: April 2023

Figure S2 shows a combination of prexasertib, cisplatin and IR in cell proliferation assays in HNSCCs.
Table S5 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Authors: Graziani Edmund I. , Sung Matthew , Ma Dangshe , Narayanan Bitha , Marquette Kimberly , Puthenveetil Sujiet , Tumey L. Nathan , Bikker Jack , Casavant Jeffrey , Bennett Eric M. , Charati Manoj B. , Golas Jonathon , Hosselet Christine , Rohde Cynthia M. , Hu George , Guffroy Magali , Falahatpisheh Hadi , Finkelstein Martin , Clark Tracey , Barletta Frank , Tchistiakova Lioudmila , Lucas Judy , Rosfjord Edward , Loganzo Frank , O'Donnell Christopher J. , Gerber Hans-Peter , Sapra Puja
Published: April 2023

Effects of Systemic Administration of Free Payload Compared with Conventional HER2-vc0101 on Indicators of Bone Marrow Toxicity and Bone Marrow Payload Levels in Rats
Supplementary Table 1 and Materials and Methods from Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors
Authors: Chen Chao , Zhu Sichao , Zhang Xia , Zhou Tingting , Gu Jing , Xu Yurong , Wan Quan , Qi Xiao , Chai Yezi , Liu Xiaorong , Chen Lukui , Yan Jie , Hua Yunfen , Lin Fan
Published: April 2023

Supplemental Table 1.-Oligonucleotide sequences.
Table S3 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Authors: Graziani Edmund I. , Sung Matthew , Ma Dangshe , Narayanan Bitha , Marquette Kimberly , Puthenveetil Sujiet , Tumey L. Nathan , Bikker Jack , Casavant Jeffrey , Bennett Eric M. , Charati Manoj B. , Golas Jonathon , Hosselet Christine , Rohde Cynthia M. , Hu George , Guffroy Magali , Falahatpisheh Hadi , Finkelstein Martin , Clark Tracey , Barletta Frank , Tchistiakova Lioudmila , Lucas Judy , Rosfjord Edward , Loganzo Frank , O'Donnell Christopher J. , Gerber Hans-Peter , Sapra Puja
Published: April 2023

Conjugation of vc0101 does not alter anti-HER2 mAb binding.
Table S2-3 from PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis
Authors: Lim James T. , Singh Neha , Leuvano Libia A. , Calvert Valerie S. , Petricoin Emanuel F. , Teachey David T. , Lock Richard B. , Padi Megha , Kraft Andrew S. , Padi Sathish K.R.
Published: April 2023

Table S2: GO terms enriched from hierarchical clustering with optimal cut tree on differentially expressed (FDR<0.01) genes in AZDR1 compared to Naïve HSB-2. Table S3: GO terms enriched from hierarchical clustering with cut tree at h=2 on differentially expressed (FDR<0.01) genes in AZDR1 compared to Naïve HSB-2.
Supplementary Figures 1-9 from A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Authors: Lesovaya Ekaterina A. , Savinkova Alena V. , Morozova Olga V. , Lylova Evgeniya S. , Zhidkova Ekaterina M. , Kulikov Evgeny P. , Kirsanov Kirill I. , Klopot Anna , Baida Gleb , Yakubovskaya Marianna G. , Gordon Leo I. , Readhead Ben , Dudley Joel T. , Budunova Irina
Published: April 2023

Supplementary Figures 1-9. Suppl. Fig. 1 contains quantification of Western blots. Suppl. Fig. 2 demonstrates the effect of PI3K/mTOR/Akt inhibitors on regulation of endogenous genes by Dex in CEM and Granta cells. Suppl. Fig. 3 shows cytotoxic effects of LY294002, Wortmannin and AZD8055 on CEM and Granta cells. Suppl. Fig. 4 demonstrates cytotoxic effects of LY294002, Wortmannin and AZD8055 on CEM cells, Granta cells and normal human monocytes. Suppl. Fig. 5 shows anti-lymphoma effect of Rapamycin and Dex in CEM and Granta cells. Suppl. Fig. 6 demonstrates the effect of LY294002, Rapamycin and Dex on animal body weight in xenograft study. Suppl. Fig. 7 shows anti-tumor effect of Dex, Rapa, LY294002 on Granta xenografts. Suppl. Fig. 8 demonstrates the effect of LY294002, Rapamycin and Dex on animal body weight in Dexamethasone-induced osteoporosis study. Suppl. Fig. 9 shows the data on Q-PCR analysis of Col1a1 and Col2a1 mRNA expression in bone tissue.
Supplementary Data Table S3 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
Authors: McDonald Gabrielle , Chubukov Victor , Coco John , Truskowski Kevin , Narayanaswamy Rohini , Choe Sung , Steadman Mya , Artin Erin , Padyana Anil K. , Jin Lei , Ronseaux Sebastien , Locuson Charles , Fan Zi-Peng , Erdmann Tabea , Mann Alan , Hayes Sebastian , Fletcher Mark , Nellore Kavitha , Rao Siva Sanjeeva , Subramanya Hosahalli , Reddy K. Satish , Panigrahi Sunil K. , Antony Thomas , Gopinath Sreevalsam , Sui Zhihua , Nagaraja Nelamangala , Dang Lenny , Lenz Georg , Hurov Jonathan , Biller Scott A. , Murtie Josh , Marks Kevin M. , Ulanet Danielle B.
Published: April 2023

GO analysis of proteins with at least a 1.5-fold increase in expression in the presence of AG-636 compared to DMSO
Table S5 from Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance
Authors: Huang Zhiqing , Kondoh Eiji , Visco Zachary R. , Baba Tsukasa , Matsumura Noriomi , Dolan Emma , Whitaker Regina S. , Konishi Ikuo , Fujii Shingo , Berchuck Andrew , Murphy Susan K.
Published: April 2023

Functional annotations (from the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8) for genes with higher expression in cells with high spheroid-forming capacity relative to cells with low spheroid-forming capacity.
Table S3 from Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance
Authors: Huang Zhiqing , Kondoh Eiji , Visco Zachary R. , Baba Tsukasa , Matsumura Noriomi , Dolan Emma , Whitaker Regina S. , Konishi Ikuo , Fujii Shingo , Berchuck Andrew , Murphy Susan K.
Published: April 2023

Differentially expressed genes that exhibit increased expression in the high spheroid-forming capacity cell lines that discriminate between high and low potential to survive serum-free spheroid culture.
Supplementary Information from Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance
Authors: Huang Zhiqing , Kondoh Eiji , Visco Zachary R. , Baba Tsukasa , Matsumura Noriomi , Dolan Emma , Whitaker Regina S. , Konishi Ikuo , Fujii Shingo , Berchuck Andrew , Murphy Susan K.
Published: April 2023

Figures S1, S2 and Tables S1,S2 and S7
Supplementary Data Figure S2 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Authors: Skidmore Lillian , Sakamuri Sukumar , Knudsen Nick A. , Hewet Amha Gebre , Milutinovic Snezana , Barkho Wisam , Biroc Sandra Lyn , Kirtley Jessica , Marsden Robin , Storey Kristine , Lopez Ianina , Yu Wayne , Fang Shiao-Yan , Yao Sulan , Gu Yi , Tian Feng
Published: April 2023

ARX788 activity in HER2-transduced MDA-MB-435 pools. MDA-MB-435 cells transduced with HER2 were sorted into pools with low, medium, and high HER2 expression and quantified for HER2 expression by QiFiKit analysis. Parental MDA-MB-435 cells and the pools were treated with ARX788 for 3 days at 37{degree sign}C, and cell viability was measured.
Supplementary Table 1 from Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors
Authors: Udhane Vindhya , Maranto Cristina , Hoang David T. , Gu Lei , Erickson Andrew , Devi Savita , Talati Pooja G. , Banerjee Anjishnu , Iczkowski Kenneth A. , Jacobsohn Kenneth , See William A. , Mirtti Tuomas , Kilari Deepak , Nevalainen Marja T.
Published: April 2023

Supplementary Table 1 a and b: Characteristics of PCs from patients.
Supplementary Figure 1 from Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors
Authors: Udhane Vindhya , Maranto Cristina , Hoang David T. , Gu Lei , Erickson Andrew , Devi Savita , Talati Pooja G. , Banerjee Anjishnu , Iczkowski Kenneth A. , Jacobsohn Kenneth , See William A. , Mirtti Tuomas , Kilari Deepak , Nevalainen Marja T.
Published: April 2023

ENZ-induced activated Stat5 is capable of nuclear translocation in PC cells.
Supplementary Figures from HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction
Authors: Qiu Yaqi , Maione Federica , Capano Stefania , Meda Claudia , Picconi Orietta , Brundu Serena , Pisacane Alberto , Sapino Anna , Palladino Clelia , Barillari Giovanni , Monini Paolo , Bussolino Federico , Ensoli Barbara , Sgadari Cecilia , Giraudo Enrico
Published: April 2023

Supplementary Figure S1, S2, S3, S4, S5
Figure S6 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Authors: Mizushima Taichi , Jiang Guiyang , Kawahara Takashi , Li Peng , Han Bin , Inoue Satoshi , Ide Hiroki , Kato Ikuma , Jalalizadeh Mehrsa , Miyagi Etsuko , Fukuda Mitsunori , Reis Leonardo O. , Miyamoto Hiroshi
Published: April 2023

Effects of Rab27b overexpression or knockdown on the expression of AR, Rab27a, and SYTL3, as well as fibronectin/integrin and macropinocytosis-related molecules, in bladder cancer cells.
Figure S4 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Authors: Mizushima Taichi , Jiang Guiyang , Kawahara Takashi , Li Peng , Han Bin , Inoue Satoshi , Ide Hiroki , Kato Ikuma , Jalalizadeh Mehrsa , Miyagi Etsuko , Fukuda Mitsunori , Reis Leonardo O. , Miyamoto Hiroshi
Published: April 2023

Effects of Rab27b/SYTL3 knockdown or GW4869 treatment on the proliferation of bladder cancer cells.
Figure S2 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Authors: Mizushima Taichi , Jiang Guiyang , Kawahara Takashi , Li Peng , Han Bin , Inoue Satoshi , Ide Hiroki , Kato Ikuma , Jalalizadeh Mehrsa , Miyagi Etsuko , Fukuda Mitsunori , Reis Leonardo O. , Miyamoto Hiroshi
Published: April 2023

Effects of androgen on BCG cytotoxicity in bladder cancer cells.
Figure S5 from An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
Authors: Deng Shanshan , Krutilina Raisa I. , Wang Qinghui , Lin Zongtao , Parke Deanna N. , Playa Hilaire C. , Chen Hao , Miller Duane D. , Seagroves Tiffany N. , Li Wei
Published: April 2023

Figures S5 shows that body weight changes and histopathology of visceral organs following tail vein injection of MDA-MB-231 cells. VERU-111 exhibits potent anti-metastasis effects. (A) Percent change in body weight {plus minus} SEM over time relative to starting body weight of mice in the vehicle (blue circles), paclitaxel (red triangles) or VERU-111-treated (green squares) cohorts (n = 7 mice/group). Only mice in the VERU-111 group continued to gain weight over the course of the experiment. Untreated mice that develop lung metastases typically lose body weight as they approach morbidity. (B) Representative H&E-stained slides of the metastases present in the lungs, livers, and kidneys harvested from mice in each cohort; examples of metastatic lesions are indicated by yellow arrows.
Figure S1 from Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity
Authors: Kim Sang-In , Park Anthony K. , Chaurasiya Shyambabu , Kang Seonah , Lu Jianming , Yang Annie , Sivanandam Venkatesh , Zhang Zhifang , Woo Yanghee , Priceman Saul J. , Fong Yuman , Warner Susanne G.
Published: April 2023

T cells isolated from cured mice show tumor-specific memory and stronger virus-specific memory (18 hours). A. ELISA from supernatants of co-cultures collected at 18 hours showing IFNγ levels in each treatment group. While some IFNγ secretion is seen when T cells are co-cultured with MC38-Luc, IFNγ production increases significantly following viral infection. B. Co-culture performed with and without MHC-I blockade shows decreased IFNγ production from activated T cells. C. MCH-II blockade leads to no changes in IFNγ production.
Supplementary Figure 6 from The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils
Authors: Bernhard Muriel Charlotte , Zwick Anabel , Mohr Tobias , Gasparoni Gilles , Khalmurzaev Oybek , Matveev Vsevolod Borisovich , Loertzer Philine , Pryalukhin Alexey , Hartmann Arndt , Geppert Carol-Immanuel , Loertzer Hagen , Wunderlich Heiko , Naumann Carsten Maik , Kalthoff Holger , Junker Kerstin , Smola Sigrun , Lohse Stefan
Published: April 2023

Supplementary Figure 6
Supplementary Figure 5 from The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils
Authors: Bernhard Muriel Charlotte , Zwick Anabel , Mohr Tobias , Gasparoni Gilles , Khalmurzaev Oybek , Matveev Vsevolod Borisovich , Loertzer Philine , Pryalukhin Alexey , Hartmann Arndt , Geppert Carol-Immanuel , Loertzer Hagen , Wunderlich Heiko , Naumann Carsten Maik , Kalthoff Holger , Junker Kerstin , Smola Sigrun , Lohse Stefan
Published: April 2023

Supplementary Figure 5
Supplementary Figure 4 from The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils
Authors: Bernhard Muriel Charlotte , Zwick Anabel , Mohr Tobias , Gasparoni Gilles , Khalmurzaev Oybek , Matveev Vsevolod Borisovich , Loertzer Philine , Pryalukhin Alexey , Hartmann Arndt , Geppert Carol-Immanuel , Loertzer Hagen , Wunderlich Heiko , Naumann Carsten Maik , Kalthoff Holger , Junker Kerstin , Smola Sigrun , Lohse Stefan
Published: April 2023

Supplementary Figure 4
Supplementary Figure 3 from The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils
Authors: Bernhard Muriel Charlotte , Zwick Anabel , Mohr Tobias , Gasparoni Gilles , Khalmurzaev Oybek , Matveev Vsevolod Borisovich , Loertzer Philine , Pryalukhin Alexey , Hartmann Arndt , Geppert Carol-Immanuel , Loertzer Hagen , Wunderlich Heiko , Naumann Carsten Maik , Kalthoff Holger , Junker Kerstin , Smola Sigrun , Lohse Stefan
Published: April 2023

Supplementary Figure 3
Supplementary Table 4 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

KRAS mutation status of cell lines included in in vitro combination screen
Supplementary Table 2 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

Response of 747 cell lines to treatment with AZD0364 for 72 hours.
Supplementary Table 1 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

Primers used for targeted gene profiling on selected RAS/MAPK pathway genes either on Fluidigm or by qRT-PCR on Roche Lightcycler 480
Supplementary Figure Legends from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 4 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

Supplementary Figure 4
Supplementary Figure 3 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

Supplementary Figure 3
Supplementary Figure 2 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

Supplementary Figure 2
Supplementary Figure 1 from AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Authors: Flemington Vikki , Davies Emma J. , Robinson David , Sandin Linda C. , Delpuech Oona , Zhang Pei , Hanson Lyndsey , Farrington Paul , Bell Sigourney , Falenta Katarzyna , Gibbons Francis D. , Lindsay Nicola , Smith Aaron , Wilson Joanne , Roberts Karen , Tonge Michael , Hopcroft Philip , Willis Sophie E. , Roudier Martine P. , Rooney Claire , Coker Elizabeth A. , Jaaks Patricia , Garnett Mathew J. , Fawell Stephen E. , Jones Clifford D. , Ward Richard A. , Simpson Iain , Cosulich Sabina C. , Pease J. Elizabeth , Smith Paul D.
Published: April 2023

Supplementary Figure 1
Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling
Authors: Van De Vyver Arthur J. , Weinzierl Tina , Eigenmann Miro J. , Frances Nicolas , Herter Sylvia , Buser Regula B. , Somandin Jitka , Diggelmann Sarah , Limani Florian , Lehr Thorsten , Bacac Marina , Walz Antje-Christine
Published: April 2023

Experimental data triplicate values with model fit
Figure S7 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Authors: Al-Khami Amir A. , Youssef Sawsan , Abdiche Yasmina , Nguyen HoangKim , Chou Joyce , Kimberlin Christopher R. , Chin Sherman M. , Kamperschroer Cris , Jessen Bart , Kern Brent , Budimir Natalija , Dillon Christopher P. , Xu Allison , Clark Jerry D. , Chou Jeffrey , Kraynov Eugenia , Rajpal Arvind , Lin John C. , Salek-Ardakani Shahram
Published: April 2023

Supplementary Figure 7 shows the binding of sasanlimab to PD-1 by ELISA
Figure S3 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Authors: Al-Khami Amir A. , Youssef Sawsan , Abdiche Yasmina , Nguyen HoangKim , Chou Joyce , Kimberlin Christopher R. , Chin Sherman M. , Kamperschroer Cris , Jessen Bart , Kern Brent , Budimir Natalija , Dillon Christopher P. , Xu Allison , Clark Jerry D. , Chou Jeffrey , Kraynov Eugenia , Rajpal Arvind , Lin John C. , Salek-Ardakani Shahram
Published: April 2023

: Supplementary Figure 3 shows the analysis of the primary structure of sasanlimab by LC-MS peptide mapping.
Figure S15 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Authors: Al-Khami Amir A. , Youssef Sawsan , Abdiche Yasmina , Nguyen HoangKim , Chou Joyce , Kimberlin Christopher R. , Chin Sherman M. , Kamperschroer Cris , Jessen Bart , Kern Brent , Budimir Natalija , Dillon Christopher P. , Xu Allison , Clark Jerry D. , Chou Jeffrey , Kraynov Eugenia , Rajpal Arvind , Lin John C. , Salek-Ardakani Shahram
Published: April 2023

Supplementary Figure 15 shows no body weight changes in response to sasanlimab treatment in mice.
Figure S12 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Authors: Al-Khami Amir A. , Youssef Sawsan , Abdiche Yasmina , Nguyen HoangKim , Chou Joyce , Kimberlin Christopher R. , Chin Sherman M. , Kamperschroer Cris , Jessen Bart , Kern Brent , Budimir Natalija , Dillon Christopher P. , Xu Allison , Clark Jerry D. , Chou Jeffrey , Kraynov Eugenia , Rajpal Arvind , Lin John C. , Salek-Ardakani Shahram
Published: April 2023

Supplementary Figure 12 shows the ELISA assay with the dose-dependent C1q binding to plate-adsorbed sasanlimab and the ADCC assay of sasanlimab performed with activated T cells (target cells) and stimulated PBMCs (effector cells).
Figure S11 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Authors: Al-Khami Amir A. , Youssef Sawsan , Abdiche Yasmina , Nguyen HoangKim , Chou Joyce , Kimberlin Christopher R. , Chin Sherman M. , Kamperschroer Cris , Jessen Bart , Kern Brent , Budimir Natalija , Dillon Christopher P. , Xu Allison , Clark Jerry D. , Chou Jeffrey , Kraynov Eugenia , Rajpal Arvind , Lin John C. , Salek-Ardakani Shahram
Published: April 2023

Supplementary Figure 11 shows sasanlimab binding to human and cynomolgus monkey Fcγ receptor and FcRn
Figure S10 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Authors: Al-Khami Amir A. , Youssef Sawsan , Abdiche Yasmina , Nguyen HoangKim , Chou Joyce , Kimberlin Christopher R. , Chin Sherman M. , Kamperschroer Cris , Jessen Bart , Kern Brent , Budimir Natalija , Dillon Christopher P. , Xu Allison , Clark Jerry D. , Chou Jeffrey , Kraynov Eugenia , Rajpal Arvind , Lin John C. , Salek-Ardakani Shahram
Published: April 2023

Supplementary Figure 10 shows the selectivity of sasanlimab binding to human and cynomolgus monkey PD-1 using HEK-293T transiently transfected cells and flow cytometry
Figure S1 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Authors: Al-Khami Amir A. , Youssef Sawsan , Abdiche Yasmina , Nguyen HoangKim , Chou Joyce , Kimberlin Christopher R. , Chin Sherman M. , Kamperschroer Cris , Jessen Bart , Kern Brent , Budimir Natalija , Dillon Christopher P. , Xu Allison , Clark Jerry D. , Chou Jeffrey , Kraynov Eugenia , Rajpal Arvind , Lin John C. , Salek-Ardakani Shahram
Published: April 2023

Supplementary Figure 1 shows the complete, confirmed amino acid sequence of sasanlimab
Supplementary Data from Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro
Authors: Kohrt Sarah E. , Awadallah Wisam N. , Phillips Robert A. , Case Thomas C. , Jin Renjie , Nanda Jagpreet S. , Yu Xiuping , Clark Peter E. , Yi Yajun , Matusik Robert J. , Anderson Philip D. , Grabowska Magdalena M.
Published: April 2023

Supplemental Figures 1-5 with figure legends embedded.
Supplementary Figure 3 from V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer
Authors: Whitton Bradleigh , Okamoto Haruko , Rose-Zerilli Matthew , Packham Graham , Crabb Simon J.
Published: April 2023

Figure S3 shows V-ATPase inhibition in DuCaP cells
Figure S2 from Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck
Authors: van Caloen Gabrielle , Schmitz Sandra , El Baroudi Mariama , Caignet Xavier , Pyr dit Ruys Sébastien , Roger Pierre P. , Vertommen Didier , Machiels Jean-Pascal
Published: April 2023

Figure S2 shows the protein expression of Cyclin E1 in HPV-negative SCCHN human cell lines.
Supplementary Figure 3 from DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization
Authors: Chandrakesan Parthasarathy , Panneerselvam Janani , May Randal , Weygant Nathaniel , Qu Dongfeng , Berry William R. , Pitts Kamille , Stanger Ben Z. , Rao Chinthalapally V. , Bronze Michael S. , Houchen Courtney W.
Published: April 2023

Dclk1+ tumor cells and myeloid cells increased in the PDAC tissue samples compared to pre-neoplastic pancreatic tissues, while the CD8+ T-cell showed a mere change in their population. Fixed pancreatic tissues from 5 weeks and 20-week old KPCY mice were stained for Dclk1, CD11B, and CD8. Bar graph representing the percentage positive staining intensity between the tissue samples, quantified using ImageJ. All quantitative data are expressed as means {plus minus} SD and P values of <0.05Ã¢â,¬â€°=Ã¢â,¬â€°*, <0.01Ã¢â,¬â€°=Ã¢â,¬â€°**, and 0.001Ã¢â,¬â€°=Ã¢â,¬â€°*** were considered statistically significant.
Supplementary Data from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Zhang Lu , Cai Tianyu , Lin Xiaoyu , Huang Xiaoli , Bui Mai H. , Plotnik Joshua P. , Bellin Richard J. , Faivre Emily J. , Kuruvilla Vinitha M. , Lam Lloyd T. , Lu Xin , Zha Zheng , Feng Weiguo , Hessler Paul , Uziel Tamar , Zhang Qi , Cavazos Antonio , Han Lina , Ferguson Debra C. , Mehta Gaurav , Shanmugavelandy Sriram S. , Magoc Terrance J. , Rowe Jenny , Goodwin Neal C. , Dorritie Kathleen A. , Boyiadzis Michael , Albert Daniel H. , McDaniel Keith F. , Kati Warren M. , Konopleva Marina , Shen Yu
Published: April 2023

Supplementary figure and table legends
Supplementary Tables and Figures from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
Authors: Nassar Kelsey W. , Hintzsche Jennifer D. , Bagby Stacey M. , Espinoza Veronica , Langouët-Astrié Christophe , Amato Carol M. , Chimed Tugs-Saikhan , Fujita Mayumi , Robinson William , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

Supplementary tables and figures
Supplementary Table S1 from A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma
Authors: Li Marina , Lin Cindy , Deng Hui , Strnad Joann , Bernabei Luca , Vogl Dan T. , Burke James J. , Nefedova Yulia
Published: April 2023

Table S1 shows biochemical potency and selectivity of BMS-P5 for PAD4
Supplementary methods from Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth
Authors: Trotta Francesca , Avena Paola , Chimento Adele , Rago Vittoria , De Luca Arianna , Sculco Sara , Nocito Marta C. , Malivindi Rocco , Fallo Francesco , Pezzani Raffaele , Pilon Catia , Lasorsa Francesco M. , Barile Simona N. , Palmieri Luigi , Lerario Antonio M. , Pezzi Vincenzo , Casaburi Ivan , Sirianni Rosa
Published: April 2023

Supplementary methods
Supplementary Table 1 from Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma
Authors: Ebelt Nancy D. , Zuniga Edith , Passi Kevin B. , Sobocinski Lukas J. , Manuel Edwin R.
Published: April 2023

Supplementary Table 1 describes the parental strains and mutations used to generate attenuated ST strains.